Updated on 26 August 2014
MyCare tests maximize chemotherapy’s effectiveness and limit potential side effects
Singapore: China-based Fosun diagnostics and Saladax Biomedical announced the launch of MyCare assay tests for chemotherapy in China. Saladax Biomedical in partnership with Fosun diagnostics has designed customized chemotherapy dosing for patients.
MyCare tests provide oncologists with specific information about each patient's exposure to chemotherapy drug, helping the doctor to make informed decisions on dose adjustments. These tests were designed after extensive patient trials conducted by Saladax.
Mr Ted Zhu, CEO, Fosun Diagnostics, said, "MyCare assays are blood tests that provide healthcare practitioners with a way to manage each patient individually and design the best suitable treatment for them." He added that such personalized cancer care would help in increasing the effectiveness of chemotherapy and reducing side effects.
MyCare kits have received approval from Chinese Food and Drug Administration. Fosun aims to manage distributors and work directly with large healthcare facilities and oncologists to make this technology available to the large Chinese market. Mr Zhu added that he was very pleased to bring this personalized care to the Chinese.
Mr Kevin M Harter, president and CEO of Saladax said, "The launch of Saladax's MyCare tests in China represents an important milestone for Saladax. With Fosun partnering us, we have high expectations from this market."
The MyCare technology platform covers 80 percent to 90 percent of the routine anti-tumor drug monitoring market. For its accurate and authentic results, the MyCare technology platform and product portfolio are in a leading position in the world, for cancer care.